ChristianaCare

All visitors are required to wear masks.

For COVID-19 safety, all visitors to ChristianaCare facilities and services are required to wear masks. This includes visitors who are vaccinated. Please read our visitor guidelines before arrival.

Masks required at outpatient locations; visitors and support persons limited

All visitors at outpatient locations must be masked in alignment with the masking guidelines on our visitation policy page here. Patients at ChristianaCare’s outpatient services are advised to come to their appointments alone unless a support person is absolutely needed. If a support person is needed, such as a parent, guardian or spokesperson, we highly encourage that the support person be vaccinated. Outpatient practices are not requiring vaccination or a negative COVID test for visitors at this time.

All hospital visitors required to be vaccinated or have a negative COVID-19 test.

  • Inpatients in our Christiana, Wilmington and Union hospitals may have one visitor daily between 10 a.m. and 8 p.m. The visitor must be 16 or older.
  • Patients having outpatient surgery may have one support person accompany them. Support persons must be 16 or older.
  • All visitors and surgical support people must show proof of vaccination OR a negative COVID-19 test within the prior 72 hours.

Before visiting, click here for more details about visitation.

Visit coronavirus.delaware.gov or cecilcountyhealth.org for local vaccination and testing sites.

Cancer Research

 

At ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Dr. Bruce Boman conducts cancer research at ChristianaCare Dr. Pradhan-Bhatt leads cancer research at ChristianaCare Dr. Eric Kmiec conducts gene editing cancer research at ChristianaCare Dr. Mourtada conducts radiation oncology cancer research at ChristianaCare Dr. Sims-Mourtada irradiates a cancer research specimen at ChristianaCare

At ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, ground-breaking cancer research is every-day reality. The Graham Cancer Center brings scientists and clinicians together to investigate innovative ways to diagnose cancer earlier and treat it more effectively.

Because of its membership in the prestigious National Cancer Institute NCI Community Oncology Research Program (NCORP), the Graham Cancer Center offers leading-edge NCORP clinical trials to the patients we are privileged to serve. The Graham Cancer Center also offers a robust pharmaceutical clinical trials program.

In addition to clinical trials, the Graham Cancer Center has a translational cancer research program, the Cawley Center for Translational Cancer Research (CTCR) that brings scientific discoveries from the bench to the bedside of patients, investigating breast cancer, colon cancer, radiation oncology and tissue engineering. The Graham Cancer Center conducts industry-leading genetic engineering cancer research at the Gene Editing Institute.

The Graham Cancer Center collaborates with other institutions in cancer research, having close partnerships with The Wistar Institute, the University of Delaware, Nemours / A.I. du Pont Hospital for Children, Rice University / BioScience Research Collaborative and the Delaware Biotechnology Institute, among others.